OCTP OXFORD CANNABINOID TECH HLDGS PLC

EQS-News: Oxford Cannabinoid Technologies appoints new CEO

EQS-News: Oxford Cannabinoid Technologies Holdings PLC
Oxford Cannabinoid Technologies appoints new CEO

05.12.2022 / 15:38 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive UK Ltd

3


News Source: News Direct

05.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Oxford Cannabinoid Technologies Holdings PLC
United States
ISIN: GB00BMVMRB86
EQS News ID: 1505463

 
End of News EQS News Service

1505463  05.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1505463&application_name=news&site_id=research_pool
EN
05/12/2022

Underlying

OCTPOXFORD CANNABINOID TECH HLDGS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OXFORD CANNABINOID TECH HLDGS PLC

Sean Conroy
  • Sean Conroy
OCTP OXFORD CANNABIN...

Oxford Cannabinoid Technologies - Termination of coverage

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

OCTP OXFORD CANNABINOID TECH HLDGS PLC
07/01/24 July 1, 2024 1 EN
Sean Conroy
  • Sean Conroy
OCTP OXFORD CANNABIN...

Oxford Cannabinoid Technologies - Early signs of revival in clinical a...

Oxford Cannabinoid Technologies (OCT) has announced its H124 results (to end-October 2023), an eventful period for the company, marked by successful clinical progression of lead asset OCT461201, albeit with some funding challenges. Key highlights included the initiation and subsequent positive safety data from OCT’s first Phase I clinical trial (Programme 1) and a foray into oncology (Programme 4). Tight funding conditions halted subsequent clinical progress, although the recently announced £1.3...

OCTP OXFORD CANNABINOID TECH HLDGS PLC
02/05/24 February 5, 2024 1 EN
Sean Conroy
  • Sean Conroy
OCTP OXFORD CANNABIN...

Oxford Cannabinoid Technologies - Poised to progress to Phase II pendi...

Oxford Cannabinoid Technologies (OCT) has announced the completion of its Phase I trial, a single ascending dose study for its lead drug candidate, OCT461201. The results of the Phase I study demonstrated safety and tolerability across the tested doses and OCT will prepare to proceed to Phase II provided it is able to raise funds in a timely manner. We continue to expect the subsequent Phase II trial to be conducted in patients with neuropathic pain associated with chemotherapy-induced periphera...

OCTP OXFORD CANNABINOID TECH HLDGS PLC
10/12/23 October 12, 2023 1 EN
Sean Conroy
  • Sean Conroy
OCTP OXFORD CANNABIN...

Oxford Cannabinoid Technologies - Clinical headway rests on funding

Oxford Cannabinoid Technologies (OCT) has shared its FY23 results and summarised its ongoing activities. OCT completed preclinical research for OCT461201 (programme 1) and in July 2023 the first healthy volunteer was dosed in the Phase I safety study; results are expected in Q3 CY23. Management believes this programme will be Phase II ready by Q4 CY23, and plans to target neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) and visceral pain in irritable bowel syndr...

OCTP OXFORD CANNABINOID TECH HLDGS PLC
09/12/23 September 12, 2023 1 EN
Daniel Appiah ... (+3)
  • Daniel Appiah
  • John Savin PhD
  • Robin Davison
OCTP OXFORD CANNABIN...

OCT enters clinical development with 201

Oxford Cannabinoid Technologies (OCT) develops a range of cannabinoid-derived pharmaceuticals. The key news is that the Phase 1 dose and safety study of its lead indication OCT461201 (“201”) with up to 32 volunteers has started.The phase I should be followed by a phase II in patients with establish

OCTP OXFORD CANNABINOID TECH HLDGS PLC
07/27/23 July 27, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch